Trial reportLeukemia2000
Prognostic factors in infants with acute myeloid leukemia.
Trial report in Leukemia, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Pooled it
- Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials.Leukemia · 2005Trial
- Article
- Long noncoding RNAs as regulators of pediatric acute myeloid leukemia.Molecular and cellular pediatrics · 2022Review
- Whole exome sequencing of pediatric leukemia reveals a novel InDel within FLT-3 gene in AML patient from Mizo tribal population, Northeast India.BMC genomic data · 2022Article
- Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia.Pediatric blood & cancer · 2021Article
- Acute Leukemia in Infants.Current oncology reports · 2021Review
- Is Acute Myeloblastic Leukemia in Children Under 2 Years of Age a Specific Entity? A Report from the FRENCH ELAM02 Study Group.HemaSphere · 2019Article
- Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience.European journal of pediatrics · 2017Article
- Article
- Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.Annals of hematology · 2017Article
- Acute myeloid leukemia in infants: biology and treatment.Frontiers in pediatrics · 2015Review
- Article
- Identification of somatic and germline mutations using whole exome sequencing of congenital acute lymphoblastic leukemia.BMC cancer · 2013Article
- Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.Leukemia · 2012Article
- The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study.Pediatric blood & cancer · 2010Article
- Eye shielding during total body irradiation for bone marrow transplantation in children transplanted for a hematological disorder: risks and benefits.Bone marrow transplantation · 2003Article
- Article
- Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome.Bone marrow transplantation · 2001Article
- Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukaemia.Leukemia · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Little is known about the factors that affect treatment outcome in very young children with acute myeloid leukemia (AML). We therefore analyzed the prognostic impact of various presenting clinical and laboratory features by discrete age group in 299 children with AML treated in four consecutive clinical trials between 1980 and 1997. Differences in presenting features, as well as treatment outcome, were compared between children aged 12 months or less (n = 28) or 13 to 24 months (n = 28) and those more than 24 months of age (n = 243). Children in the two youngest groups (24 months of age or less) had similar presenting features and treatment outcome. Collectively, these 56 children were significantly more likely than the 243 older patients to have M4 or M5 leukemia (70% vs 30%), CNS leukemia (33% vs 22%), the t(9;11) (p22;q23) (18% vs 6%) or other 11q23 translocations (23% vs 3%), and less likely to have Auer rods (2% vs 54%) or the t(8;21) (q22;q22) (0% vs 17%). Among patients aged 24 months or less, two factors independently predicted a favorable prognosis: FAB M4 or M5 leukemia (relative risk of relapse, 0.4; 95% confidence interval, 0.2-0.9) and the t(9;11) (relative risk, 0.3; 95% confidence interval, 0.1-1.0). Leukocyte count and 11q23 translocations other than the t(9;11) lacked prognostic significance. Among older patients, a leukocyte count <50 x 10(9)/l and the presence of the t(9;11) conferred a favorable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.